Physician profile
Sonia Michael
NPI 1063467983
$246.64
in general payments reported to CMS, 2019-2025
3 companies · $20.62 in 2025
The $20.62 reported for 2025 was less than what a typical Adult Medicine provider received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $123 · 2021: $78.32 · 2022: $24.98 · 2025: $20.62.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $20.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $20.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $121.36 | 2020-2025 | Ams 700 |
| Abbott Laboratories | $100.30 | 2020-2021 | |
| Alexion Pharmaceuticals, INC. | $24.98 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonia Michael listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.